Celltech - a European biotechnology leader
Major advances in 2001 to improve risk profile and significantly augment shareholder value
- CDP 870 Pharmacia collaboration
- Merck PDE IV programme in Ph II
- BMS MMPI programme in Ph II/III
- Boss/Cabilly settlement with Genentech